Harvard Skin Disease Research Center, Department of Dermatology, Brigham and Women's Hospital, Harvard Institutes of Medicine, 77 Avenue Louis Pasteur, Boston, MA 02115, USA.
Arch Dermatol Res. 2010 Aug;302(6):453-9. doi: 10.1007/s00403-009-1023-x. Epub 2010 Jan 29.
In advanced stages, cutaneous T cell lymphomas (CTCL) are associated with increased mortality from infections and also increased susceptibility to skin malignancies. In this study, we analyzed the complexity of the peripheral blood T cell repertoire with a sensitive b-variable (BV) complementarity-determining region 3 (CDR3) spectratyping analysis and flow cytometry in three-stage IV CTCL/Sezary syndrome patients who achieved complete clinical remission after therapy. The T cell repertoire of peripheral blood T cells before treatment was profoundly abnormal across multiple BV subfamilies. Following treatment, CDR3 spectratype patterns showed dramatic restoration of normal diversity and complexity. However, absolute CD4 counts across multiple BV families remained low for many months, even after identifiable circulating malignant T cell populations were eliminated. These data suggest that the diversity of the T cell repertoire can be recovered after successful treatment of even advanced CTCL.
在晚期，皮肤 T 细胞淋巴瘤（CTCL）与感染导致的死亡率增加以及皮肤恶性肿瘤的易感性增加有关。在这项研究中，我们通过敏感的 b 变量（BV）互补决定区 3（CDR3）谱型分析和流式细胞术分析了三位处于 IV 期 CTCL/Sezary 综合征的患者，他们在治疗后达到完全临床缓解。治疗前，外周血 T 细胞的 T 细胞受体库在多个 BV 亚家族中存在严重异常。治疗后，CDR3 谱型模式显示正常多样性和复杂性显著恢复。然而，即使在可识别的循环恶性 T 细胞群被消除后，多个 BV 家族的绝对 CD4 计数仍持续数月保持较低水平。这些数据表明，即使是晚期 CTCL 的成功治疗后，T 细胞受体库的多样性也可以恢复。
